<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138037">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125981</url>
  </required_header>
  <id_info>
    <org_study_id>LIMA_001</org_study_id>
    <nct_id>NCT02125981</nct_id>
  </id_info>
  <brief_title>The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy</brief_title>
  <official_title>A Prospective Randomized Double-blinded Clinical Trial About the Efficacy of Oral Limaprost Administration Following Surgery for Cervical Myelopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The limaprost alfadex can improve the surgical outcomes in patients with cervical
      myelopathy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Japanese Orthopedic  Association (JOA) recovery rates</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>JOA recovery rate = [(postoperative JOA score) - (preoperative JOA score)] / [(17-(preoperative JOA score)] x 100 (%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Pain Scale for neck pain</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck disability index score</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japanese orthopaedic association Cervical Myelopathy Evaluation Questionnaire score</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire Short Form 12</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japanese orthopaedic association score</measure>
    <time_frame>up to 12 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the efficacy of positron emission tomography (PET)</measure>
    <time_frame>up to 12 months after operation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The assessment of the efficacy of PET for prediction of drug (Limaprost) effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cervical Myelopathy</condition>
  <arm_group>
    <arm_group_label>Limaprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking  Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>taking placebo drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Limaprost</intervention_name>
    <description>taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day</description>
    <arm_group_label>Limaprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>taking placebo drug</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 20 years old

          -  compressive cervical myelopathy, confirmed by MRI, including C1-C2 instability,
             ossification of posterior longitudinal ligament

          -  plan to undergo cervical surgery for myelopathy

          -  JOA score less than 15 points

          -  signed informed consent of patient or legal guardian

        Exclusion Criteria:

          -  infection or malignancy

          -  taking Limaprost before surgery

          -  pregnancy or expected to be pregnant or breast feeding

          -  severe cardiovascular, pulmonary, renal disease or distress, brain pathology

          -  any related coagulopathy

          -  any drug to cause bleeding tendency

          -  severe pain from other disease

          -  any other significant disease or disorder which, in the opinion of the Investigator,
             may either put the participants at risk because of participation in the study, or may
             influence the result of the study

          -  patient cannot follow study protocol, for any reason
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin S. Yeom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin S. Yeom, MD</last_name>
    <phone>82-31-787-7195</phone>
    <email>highcervical@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Sung-Nam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin S. Yeom, MD</last_name>
      <phone>+82-31-787-7915</phone>
      <email>highcervical@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jin S. Yeom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>April 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin S. Yeom</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>limaprost alfadex</keyword>
  <keyword>cervical myelopathy</keyword>
  <keyword>surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Spinal Cord Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
